Capstone Therapeutics Corp. (NASDAQ:CAPS – Get Free Report) was the recipient of a large drop in short interest in October. As of October 15th, there was short interest totaling 696,378 shares, a drop of 65.6% from the September 30th total of 2,025,068 shares. Based on an average daily trading volume, of 1,178,085 shares, the days-to-cover ratio is presently 0.6 days. Currently, 130.4% of the shares of the company are short sold.
Capstone Therapeutics Stock Performance
CAPS traded down $0.51 during midday trading on Friday, reaching $2.22. The company had a trading volume of 105,667 shares, compared to its average volume of 44,869. Capstone Therapeutics has a 12-month low of $2.11 and a 12-month high of $34.80. The business has a 50-day moving average price of $4.45 and a two-hundred day moving average price of $11.00. The stock has a market cap of $1.95 million, a PE ratio of -0.02 and a beta of -1.50. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.39 and a current ratio of 0.99.
Analyst Ratings Changes
Separately, Weiss Ratings raised Capstone Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 23rd. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, Capstone Therapeutics presently has a consensus rating of “Sell”.
Get Our Latest Research Report on Capstone Therapeutics
Capstone Therapeutics Company Profile
Capstone Therapeutics Corporation was a biotechnology company focused on developing peptide-based therapeutics for tissue repair and regenerative medicine. Its research programs centered on synthetic peptides designed to influence healing and recovery in areas such as bone, soft tissue and cardiovascular injury.
The company’s principal historical programs included Chrysalin (TP508), an experimental peptide derived from a portion of the human thrombin protein that was investigated for applications in bone and tissue healing, and AZX100, a peptide-based candidate studied for its potential to reduce fibrosis and postsurgical scarring.
Further Reading
- Five stocks we like better than Capstone Therapeutics
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Capstone Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capstone Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
